Exact Mass: 651.3254594
Exact Mass Matches: 651.3254594
Found 186 metabolites which its exact mass value is equals to given mass value 651.3254594
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
17alpha-(N-acetyl-D-glucosaminyl)estradiol 3-glucuronide
milbemycin alpha10
Naloxegol
PC(2:0/6 keto-PGF1alpha)
PC(2:0/6 keto-PGF1alpha) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/6 keto-PGF1alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(6 keto-PGF1alpha/2:0)
PC(6 keto-PGF1alpha/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(6 keto-PGF1alpha/2:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(2:0/TXB2)
PC(2:0/TXB2) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/TXB2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(TXB2/2:0)
PC(TXB2/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(TXB2/2:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
Protostreptovaricin II
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins
7-(3-Pyridinecarbonyl),3,5-dibutanoyl,15-Ac-Myrsinol
Phe His Trp Tyr
Phe His Tyr Trp
Phe Asn Trp Trp
Phe Trp His Tyr
Phe Trp Asn Trp
Phe Trp Trp Asn
Phe Trp Tyr His
Phe Tyr His Trp
Phe Tyr Trp His
His Phe Trp Tyr
His Phe Tyr Trp
His Trp Phe Tyr
His Trp Tyr Phe
His Tyr Phe Trp
His Tyr Trp Phe
Lys Arg Trp Tyr
C32H45N9O6 (651.3492630000001)
Lys Arg Tyr Trp
C32H45N9O6 (651.3492630000001)
Lys Trp Arg Tyr
C32H45N9O6 (651.3492630000001)
Lys Trp Tyr Arg
C32H45N9O6 (651.3492630000001)
Lys Tyr Arg Trp
C32H45N9O6 (651.3492630000001)
Lys Tyr Trp Arg
C32H45N9O6 (651.3492630000001)
Asn Phe Trp Trp
Asn Trp Phe Trp
Asn Trp Trp Phe
Gln Arg Trp Tyr
C31H41N9O7 (651.3128796000001)
Gln Arg Tyr Trp
C31H41N9O7 (651.3128796000001)
Gln Trp Arg Tyr
C31H41N9O7 (651.3128796000001)
Gln Trp Tyr Arg
C31H41N9O7 (651.3128796000001)
Gln Tyr Arg Trp
C31H41N9O7 (651.3128796000001)
Gln Tyr Trp Arg
C31H41N9O7 (651.3128796000001)
Arg Lys Trp Tyr
C32H45N9O6 (651.3492630000001)
Arg Lys Tyr Trp
C32H45N9O6 (651.3492630000001)
Arg Gln Trp Tyr
C31H41N9O7 (651.3128796000001)
Arg Gln Tyr Trp
C31H41N9O7 (651.3128796000001)
Arg Trp Lys Tyr
C32H45N9O6 (651.3492630000001)
Arg Trp Gln Tyr
C31H41N9O7 (651.3128796000001)
Arg Trp Tyr Lys
C32H45N9O6 (651.3492630000001)
Arg Trp Tyr Gln
C31H41N9O7 (651.3128796000001)
Arg Tyr Lys Trp
C32H45N9O6 (651.3492630000001)
Arg Tyr Gln Trp
C31H41N9O7 (651.3128796000001)
Arg Tyr Trp Lys
C32H45N9O6 (651.3492630000001)
Arg Tyr Trp Gln
C31H41N9O7 (651.3128796000001)
Trp Phe His Tyr
Trp Phe Asn Trp
Trp Phe Trp Asn
Trp Phe Tyr His
Trp His Phe Tyr
Trp His Tyr Phe
Trp Lys Arg Tyr
C32H45N9O6 (651.3492630000001)
Trp Lys Tyr Arg
C32H45N9O6 (651.3492630000001)
Trp Asn Phe Trp
Trp Asn Trp Phe
Trp Gln Arg Tyr
C31H41N9O7 (651.3128796000001)
Trp Gln Tyr Arg
C31H41N9O7 (651.3128796000001)
Trp Arg Lys Tyr
C32H45N9O6 (651.3492630000001)
Trp Arg Gln Tyr
C31H41N9O7 (651.3128796000001)
Trp Arg Tyr Lys
C32H45N9O6 (651.3492630000001)
Trp Arg Tyr Gln
C31H41N9O7 (651.3128796000001)
Trp Trp Phe Asn
Trp Trp Asn Phe
Trp Tyr Phe His
Trp Tyr His Phe
Trp Tyr Lys Arg
C32H45N9O6 (651.3492630000001)
Trp Tyr Gln Arg
C31H41N9O7 (651.3128796000001)
Trp Tyr Arg Lys
C32H45N9O6 (651.3492630000001)
Trp Tyr Arg Gln
C31H41N9O7 (651.3128796000001)
Tyr Phe His Trp
Tyr Phe Trp His
Tyr His Phe Trp
Tyr His Trp Phe
Tyr Lys Arg Trp
C32H45N9O6 (651.3492630000001)
Tyr Lys Trp Arg
C32H45N9O6 (651.3492630000001)
Tyr Gln Arg Trp
C31H41N9O7 (651.3128796000001)
Tyr Gln Trp Arg
C31H41N9O7 (651.3128796000001)
Tyr Arg Lys Trp
C32H45N9O6 (651.3492630000001)
Tyr Arg Gln Trp
C31H41N9O7 (651.3128796000001)
Tyr Arg Trp Lys
C32H45N9O6 (651.3492630000001)
Tyr Arg Trp Gln
C31H41N9O7 (651.3128796000001)
Tyr Trp Phe His
Tyr Trp His Phe
Tyr Trp Lys Arg
C32H45N9O6 (651.3492630000001)
Tyr Trp Gln Arg
C31H41N9O7 (651.3128796000001)
Tyr Trp Arg Lys
C32H45N9O6 (651.3492630000001)
Tyr Trp Arg Gln
C31H41N9O7 (651.3128796000001)
17alpha-(N-acetyl-alpha-D-glucosaminyl)estradiol 3-glucuronoside
1-hydroxy-4-(1-phenyl-1H-tetrazol-5-ylthio)-2-tetradecyloxy-2-naphthanilide
Naloxegol
A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AH - Peripheral opioid receptor antagonists D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist D013501 - Surface-Active Agents > D011092 - Polyethylene Glycols D001697 - Biomedical and Dental Materials
(2S,3S,4S,5R,6R)-6-[[(8R,9S,13S,14S,17R)-17-[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
[(10E,14E,16E)-6-ethyl-21,24-dihydroxy-5,11,13-trimethyl-2-oxospiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2-oxane]-22-yl]methyl 1H-pyrrole-2-carboxylate
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals
1-[(3R,9S,10R)-9-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-propan-2-ylurea
1-[[(3S,9S,10S)-16-[(3,5-dimethyl-4-isoxazolyl)sulfonylamino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-propan-2-ylurea
N-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide
17alpha-(N-acetyl-D-glucosaminyl)estradiol 3-glucosiduronic acid
17alpha-(N-Acetyl-D-glucosaminyl)-estradiol 3-D-glucuronide
All-trans-heptaprenyl diphosphate(3-)
An organophosphate oxoanion arising from deprotonation of the diphosphate OH groups of all-trans-heptaprenyl diphosphate; major species at pH 7.3.
Arg-Gly-Tyr-Ser-Leu-Gly
Arg-Gly-Tyr-Ser-Leu-Gly is corresponding to the sequence of residues from 21 through 26 in lysozyme. Arg-Gly-Tyr-Ser-Leu-Gly can be used as a substrate for the protein kinase, and phosphorylated at serine residue by protein kinase[1].
n-{7-benzyl-5,8-dihydroxy-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,10,12,15-hexaen-4-yl}-1-[2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboximidic acid
(2s)-n-[(3r,4s,7s,10z)-7-benzyl-5,8-dihydroxy-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,10,12,15-hexaen-4-yl]-1-[(2s)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboximidic acid
(1r,2r,3r,4r,7s,9r,10r,11r,14s)-2,3,10-tris(acetyloxy)-4,14,15,15-tetramethyl-8-methylidene-13-oxotetracyclo[9.3.1.0¹,⁹.0⁴,⁹]pentadecan-7-yl (3r)-3-(dimethylamino)-3-phenylpropanoate
7-(acetyloxy)-2,4-bis(butanoyloxy)-5,9-dimethyl-8-oxo-11-(prop-1-en-2-yl)-16-oxatetracyclo[7.5.2.0¹,¹⁰.0³,⁷]hexadec-12-en-14-yl pyridine-3-carboxylate
(2r)-n-[(3r,4r,7r,10z)-7-benzyl-5,8-dihydroxy-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,10,12,15-hexaen-4-yl]-1-[(2s)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboximidic acid
(2r,3r,4r,7s,10r,11r,14s)-2,3,10-tris(acetyloxy)-4,14,15,15-tetramethyl-8-methylidene-13-oxotetracyclo[9.3.1.0¹,⁹.0⁴,⁹]pentadecan-7-yl 3-(dimethylamino)-3-phenylpropanoate
(1s,2r,3r,4r,7s,9r,10r,11r,14s)-2,3,10-tris(acetyloxy)-4,14,15,15-tetramethyl-8-methylidene-13-oxotetracyclo[9.3.1.0¹,⁹.0⁴,⁹]pentadecan-7-yl (3r)-3-(dimethylamino)-3-phenylpropanoate
(2s)-n-[(3s,4s,7s,10z)-7-benzyl-5,8-dihydroxy-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,10,12,15-hexaen-4-yl]-1-[(2s)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboximidic acid
(2s)-2-[(1-hydroxy-2-{[(1s,2r)-2-hydroxy-1-{[(1s)-2-hydroxy-1-{[(2s)-1-(1h-indol-3-yl)-3-oxopentan-2-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}-2-methylethylidene)amino]-3-phenylpropanoic acid
C33H41N5O9 (651.2904136000001)